Feline immunodeficiency virus (FIV) infects 5-20% of cats worldwide, leading to acquired immunodeficiency syndrome (AIDS) with increased susceptibility to infections and cancer. Like HIV, FIV integrates into immune cell DNA, forming a persistent viral reservoir as proviral DNA. Currently, no licensed antiretroviral treatments exist, making FIV management purely palliative. CRISPR-Cas9-based genetic therapy offers a potential cure by eliminating FIV proviral DNA, but effective and specific delivery to FIV target cells remains a challenge. Here, we propose NanoClaws, the first targeted CRISPR-Cas9 delivery system in veterinary medicine. Two types of nanoparticles -lipid nanoparticles (LNP NanoClaws) and virus-like particles (VLP NanoClaws)- will be engineered with targeting ligands to produce a library of NanoClaws. This library will be screened to identify vectors capable of delivering CRISPR-Cas9 selectively to FIV-susceptible cells. Selected vectors will be validated in vitro using feline cell lines and primary peripheral blood mononuclear cells. Finally, we will establish a novel felinised mouse model to assess the ability of selected NanoClaws to eliminate FIV infection in an (ethically) relevant in vivo model. Interestingly, our plug-and-play nanomedicine platform as well as our novel in vivo model hold broad potential for Flanders' veterinary biotech industry not only for infectious diseases, but also for autoimmune diseases, and oncology.